Hematopoietic Stem Cell Transplantation Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hematopoietic Stem Cell Transplantation pipeline constitutes 20+ key companies continuously working towards developing 20+ Hematopoietic Stem Cell Transplantation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hematopoietic Stem Cell Transplantation Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hematopoietic Stem Cell Transplantation Market.

The Hematopoietic Stem Cell Transplantation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hematopoietic Stem Cell Transplantation Pipeline Report: https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hematopoietic Stem Cell Transplantation treatment therapies with a considerable amount of success over the years.
• Hematopoietic Stem Cell Transplantation companies working in the treatment market are Sanofi, Actinium Pharmaceuticals, Medexus Pharmaceuticals /medac Pharma, Actinium Pharmaceuticals, BioLineRx, Medexus pharma, and others, are developing therapies for the Hematopoietic Stem Cell Transplantation treatment
• Emerging Hematopoietic Stem Cell Transplantation therapies in the different phases of clinical trials are- MOZOBIL (plerixafor), Iomab-B (CD45) (apamistamab-I-131), TRECONDI (treosulfan), Treosulfan, and others are expected to have a significant impact on the Hematopoietic Stem Cell Transplantation market in the coming years.
• In February 2025, Orca Bio, a late-stage biotech company focused on advancing high-precision cell therapies to improve patient outcomes, has announced it will share positive findings from its pivotal Phase 3 Precision-T study (NCT05316701) on the investigational allogeneic T-cell immunotherapy, Orca-T, for individuals with hematologic cancers at the 51st Annual Meeting of the EBMT.
• In January 2025, Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Helocyte, Inc. ("Helocyte"), announced today that the first patient has been dosed in a multicenter, randomized, placebo-controlled Phase 2 clinical trial evaluating Triplex-a cytomegalovirus (CMV) vaccine-administered to HLA-matched related stem cell donors to help prevent CMV-related events in patients receiving hematopoietic stem cell transplants (HSCT).
• In January 2025, According to a news release from Medexus, the manufacturer, the U.S. Food and Drug Administration (FDA) has approved the alkylating agent treosulfan (Grafapex), in combination with fludarabine, as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients aged 1 year and older diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Hematopoietic Stem Cell Transplantation Overview
Hematopoietic stem cell transplant (HPSCT), also known as a bone marrow transplant, involves giving patients who have malfunctioning or depleted bone marrow viable hematopoietic stem cells. Clinical HPSCT comes in a variety of forms, and the transplanted cells might come from many sources.

Get a Free Sample PDF Report to know more about Hematopoietic Stem Cell Transplantation Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Hematopoietic Stem Cell Transplantation Drugs Under Different Phases of Clinical Development Include:
• MOZOBIL (plerixafor): Sanofi
• Iomab-B (CD45) (apamistamab-I-131): Actinium Pharmaceuticals
• TRECONDI (treosulfan): Medexus Pharmaceuticals /medac Pharma
• Iomab-B: Actinium Pharmaceuticals
• Motixafortide: BioLineRx
• Treosulfan: Medexus pharma

Hematopoietic Stem Cell Transplantation Route of Administration
Hematopoietic Stem Cell Transplantation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous

Hematopoietic Stem Cell Transplantation Molecule Type
Hematopoietic Stem Cell Transplantation Products have been categorized under various Molecule types, such as
• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Hematopoietic Stem Cell Transplantation Pipeline Therapeutics Assessment
• Hematopoietic Stem Cell Transplantation Assessment by Product Type
• Hematopoietic Stem Cell Transplantation By Stage and Product Type
• Hematopoietic Stem Cell Transplantation Assessment by Route of Administration
• Hematopoietic Stem Cell Transplantation By Stage and Route of Administration
• Hematopoietic Stem Cell Transplantation Assessment by Molecule Type
• Hematopoietic Stem Cell Transplantation by Stage and Molecule Type

DelveInsight's Hematopoietic Stem Cell Transplantation Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hematopoietic Stem Cell Transplantation product details are provided in the report. Download the Hematopoietic Stem Cell Transplantation pipeline report to learn more about the emerging Hematopoietic Stem Cell Transplantation therapies
https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Hematopoietic Stem Cell Transplantation Therapeutics Market include:
Key companies developing therapies for Hematopoietic Stem Cell Transplantation are - STEMCELL Technologies, Inc., Pluristem Therapeutics, Inc., Merck KGaA, ScienCell Research Laboratories, Inc., Lonza Group, and others.

Hematopoietic Stem Cell Transplantation Pipeline Analysis:
The Hematopoietic Stem Cell Transplantation pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hematopoietic Stem Cell Transplantation with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hematopoietic Stem Cell Transplantation Treatment.
• Hematopoietic Stem Cell Transplantation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hematopoietic Stem Cell Transplantation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hematopoietic Stem Cell Transplantation market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hematopoietic Stem Cell Transplantation drugs and therapies
https://www.delveinsight.com/sample-request/hematopoietic-stem-cell-transplantation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hematopoietic Stem Cell Transplantation Pipeline Market Drivers
• The Rise in the prevalence of Malignant Diseases, increasing Research and Developmental Activities are some of the important factors that are fueling the Hematopoietic Stem Cell Transplantation Market.

Hematopoietic Stem Cell Transplantation Pipeline Market Barriers
• However, lack of Knowledge and Risks Associated, post-HSCT Complications and other factors are creating obstacles in the Hematopoietic Stem Cell Transplantation Market growth.

Scope of Hematopoietic Stem Cell Transplantation Pipeline Drug Insight
• Coverage: Global
• Key Hematopoietic Stem Cell Transplantation Companies: Sanofi, Actinium Pharmaceuticals, Medexus Pharmaceuticals /medac Pharma, Actinium Pharmaceuticals, BioLineRx, Medexus pharma, and others
• Key Hematopoietic Stem Cell Transplantation Therapies: MOZOBIL (plerixafor), Iomab-B (CD45) (apamistamab-I-131), TRECONDI (treosulfan), Treosulfan, and others
• Hematopoietic Stem Cell Transplantation Therapeutic Assessment: Hematopoietic Stem Cell Transplantation current marketed and Hematopoietic Stem Cell Transplantation emerging therapies
• Hematopoietic Stem Cell Transplantation Market Dynamics: Hematopoietic Stem Cell Transplantation market drivers and Hematopoietic Stem Cell Transplantation market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.